At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy
In Brief
A clinical study evaluating Spinal Cord Stimulator (octopolar Medtronic Vectris Leads) for Spinal Muscular Atrophy Type 3 and Spinal Muscular Atrophy Type 4. Completed, enrolled 3 participants across 1 site.
Detailed Summary
Spinal cord stimulation (SCS) has shown remarkable efficacy in restoring motor function in people with spinal cord injury by recruiting afferent input to enhance the responsiveness of spared neural circuits to residual cortical inputs. This pilot will test if SCS can show evidence to improve motor deficits in people with type 3 or 4 spinal muscular atrophy (SMA). The investigators will enroll up to six subjects with Type 3 or 4 SMA aged 16 or older that show quantifiable motor deficits of the legs but are able to stand independently. The investigators will then implant the subjects with percutaneous, bilateral, linear spinal leads near the lumbar spinal cord for a period of up to 29 days. Although these leads are not optimized for motor function but rather for their clinically approved indication of treating pain, the investigators believe they provide a safe technology enabling our team to perform scientific measurement necessary to evaluate potential for effects of SCS in motor paralysis with SMA. After the end of the study, the leads will be explanted.
Study Details
Timeline
Interventions
2-4 leads FDA-approved for treatment of symptoms of refractory pain